DUBLIN--(BUSINESS WIRE)--The "Implantable Biomaterials - Global Market Outlook (2017-2026)" report has been added to ResearchAndMarkets.com's offering.
According to the report, the market accounted for $96.11 billion in 2017 and is expected to reach $195.47 billion by 2026 growing at a CAGR of 8.2%.
Factors such as growing geriatric inhabitants worldwide, growing incidences of diseases and graft transplant surgeries, medical implants and technological advancements will drive the market growth. However, adverse reactions to biomaterials and strict regulatory requirements are some of the factors hampering the market growth.
Based on application, the orthopedic segment is projected to grow due to growing degenerative bone diseases like osteoporosis and osteoarthritis, rising demand for minimally invasive surgeries and increase in accidents and sports injuries are factors favouring the market growth.
In terms of geography, North America holds the largest market revenue due to rise in new products and the development of new biomaterials for ophthalmology, tissue engineering, plastic surgery and wound healing are fuel the market growth in this region.
Key Topics Covered
1 Executive Summary
2 Preface
3 Market Trend Analysis
4 Porters Five Force Analysis
5 Global Implantable Biomaterials Market, By Material
6 Global Implantable Biomaterials Market, By Application
7 Global Implantable Biomaterials Market, By Geography
8 Key Developments
9 Company Profiling
- E. I. Du Pont De Nemours and Company
- BASF SE
- 3M
- Evonik Industries AG
- AdvanSource Biomaterials Corporation
- Royal DSM
- Corbion Purac
- Collagen Matrix Inc.
- Celanese Corporation
- Biomet Inc.
- Invibio Inc.
- Orthofix Holdings Inc.
- Stryker Corporation
- KLS Martin
- Medtronic
- Arthrex
- AAP Implantate AG
- Zimmer Biomet Holdings Inc.
- CAM Bioceramics BV
For more information about this report visit https://www.researchandmarkets.com/research/8vxcdj/implantable?w=4
